Zscan26: A Potential Drug Target for Disrupted Cell Processes

Target Name: ZSCAN26

NCBI ID: G7741

ZSCAN26

Zscan26: A Potential Drug Target for Disrupted Cell Processes

ZSCAN26 (ZSC26_HUMAN), a protein encoded by the human gene Zscan26, is a potential drug target and biomarker. The Zscan26 gene is located on chromosome 16 and encodes a protein that is expressed in various tissues and organs, including brain, heart, liver, and muscle.

The Zscan26 protein is known for its role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Zscan26 has been shown to play a significant role in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

One of the key functions of the Zscan26 protein is its role in the regulation of cell apoptosis. Apoptosis is a natural process that helps remove damaged or dysfunctional cells from the body, and it is a critical mechanism for maintaining tissue homeostasis and regeneration. However, in diseases such as cancer and neurodegenerative disorders, the regulation of apoptosis can be disrupted, leading to the formation of uncontrolled cells that can cause tumors and other diseases.

Zscan26 has been shown to play a role in the regulation of apoptosis by promoting the expression of genes that are involved in cell survival and by inhibiting the expression of genes that are involved in cell death. This suggests that Zscan26 may be a potential drug target for diseases that are characterized by the disruption of normal cell apoptosis.

In addition to its role in apoptosis, Zscan26 has also been shown to play a role in the regulation of angiogenesis, the formation of new blood vessels. Angiogenesis is the process by which new blood vessels are formed in the body, and it is a critical mechanism for maintaining blood flow to the body's various tissues. However, in diseases such as cancer and neurodegenerative disorders, the regulation of angiogenesis can be disrupted, leading to the formation of uncontrolled blood vessels that can cause tumors and other diseases.

Zscan26 has been shown to play a role in the regulation of angiogenesis by promoting the expression of genes that are involved in blood vessel formation and by inhibiting the expression of genes that are involved in cell signaling. This suggests that Zscan26 may be a potential drug target for diseases that are characterized by the disruption of normal angiogenesis.

The potential drug targeting of Zscan26 is based on its ability to interact with a variety of different proteins, including those involved in cell signaling, apoptosis, and angiogenesis. This makes Zscan26 a promising target for diseases that are characterized by the disruption of these processes.

In conclusion, ZSCAN26 (ZSC26_HUMAN) is a protein that is encoded by the human gene Zscan26. It is known for its role in the regulation of cell apoptosis and angiogenesis, and it has been shown to play a significant role in the development and progression of various diseases. The potential drug targeting of Zscan26 is based on its ability to interact with a variety of different proteins, including those involved in cell signaling, apoptosis, and angiogenesis. This makes Zscan26 a promising target for diseases that are characterized by the disruption of these processes. Further research is needed to fully understand the role of Zscan26 in disease and to develop effective treatments.

Protein Name: Zinc Finger And SCAN Domain Containing 26

Functions: May be involved in transcriptional regulation

The "ZSCAN26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZSCAN26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets